Wall Street equity analysts tracking Allogene Therapeutics (NASDAQ: ALLO) generally view the stock favorably, with a consensus leaning toward a buy rating. Institutional optimism is driven by clinical advancements in allogeneic CAR T cell therapies for oncology, alongside recent updates showing narrowed quarterly losses and extended cash runways. However, biotech clinical-stage risks require careful portfolio evaluation.